Nardilysin: A potential biomarker for the early diagnosis of acute coronary syndrome

The interesting finding reported in IJC by Po-Min Chen et al. [1] in regard to nardilysin as a potential early marker of acute coronary syndrome, is even more intriguing now keeping in mind the very recent report by Ito et al. [2]. The latter manuscript claims that in vitro platelet production from induced pluripotent stem cell (iPS) precursors is largely increased by applying turbulent forces in the in vitro system designed by the authors, scaling platelet yield and quality at a clinical meaningful level and paving the way for a realistic alternative to transfusion for platelet supply for the first time.